Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia

Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia

Abstract Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23 in t(6;11), which results in a poor prognosis. The...

Full description

Bibliographic Details
Main Authors: Taro Edahiro, Hiroshi Ureshino, Ren Chishaki, Keita Fujino, Tatsuji Mino, Tetsumi Yoshida, Noriyasu Fukushima, Tatsuo Ichinohe
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:eJHaem
Subjects:
11q23/MLL‐rearranged acute myeloid leukemia
azacitidine
BCL‐2
venetoclax
Online Access:https://doi.org/10.1002/jha2.630

Internet

https://doi.org/10.1002/jha2.630

Similar Items